Hyderabad: Scientists have developed an artificial intelligence (AI) model to redesign a key protein that plays a key role in gene therapy targeting various diseases. These proteins are designed to suppress the immune response, which can improve the efficacy of gene therapy, the scientists said.
Scientists from Toronto University in Canada have achieved this feat. The study, published in Nature Machine Intelligence, describes new work optimising proteins to mitigate immune responses, thereby improving the efficacy of gene therapy and reducing side effects.
“Gene therapy holds immense promise, but the body’s pre-existing immune response to viral vectors greatly hampers its success. Our research zeroes in on the hexon, a fundamental protein in adenovirus vectors, which – but for the immune problem – hold huge potential for gene therapy," says Michael Garton, an assistant professor at the Institute of Biomedical Engineering in the Faculty of Applied Science and Engineering.
"Immune responses triggered by serotype-specific antibodies pose a significant obstacle in getting these vehicles to the right target; this can result in reduced efficacy and severe adverse effects."
To address the issue, Garton’s lab used AI to custom-design variants of hexon that are distinct from natural sequences. “We want to design something that is distant from all human variants and is, by extension, unrecognisable by the immune system,” says PhD candidate Suyue Lyu, who is lead author of the study.
Traditional methods of designing new proteins often involve extensive trial and error as well as mounting costs. By using an AI-based approach for protein design, researchers can achieve a higher degree of variation, reduce costs and quickly generate simulation scenarios before homing in on a specific subset of targets for experimental testing.
While numerous protein-designing frameworks exist, it can be challenging for researchers to properly design new variants because of the lack of natural sequences available and hexons' relatively large size — consisting, on average, of 983 amino acids.
The team developed a different AI framework, dubbed ProteinVAE, that can be trained to learn the characteristics of a long protein using limited data. Despite its compact design, ProteinVAE exhibits a generative capability comparable to larger available models, the researchers said.
"Our model takes advantage of pre-trained protein language models for efficient learning on small datasets. We also incorporated many tailored engineering approaches to make the model suitable for generating long proteins," said Lyu.
"Unlike other, considerably larger models that demand high computational resources to design a long protein, ProteinVAE supports fast training and inference on any standard GPUs. This feature could make the model more friendly for other academic labs," the researcher said.
The researchers noted that the AI model, validated through molecular simulation, demonstrates the ability to change a significant percentage of the protein's surface, potentially evading immune responses. Garton believes the AI model can be utilised beyond gene therapy protein design and could likely be expanded to support protein design in other disease cases as well.
"This work indicates that we are potentially able to design new subspecies and even species of biological entities using generative AI and these entities have therapeutic value that can be used in novel medical treatments," Garton added.
Read More
- Forget Fingerprints or Face Recognition, Soon Your Breath Can be Used to Unlock Smartphones
- Generative AI likely to become $100 bn industry by 2026: Report
- CSIR launches tech-driven initiative to improve productivity, farmers' income
